John K. Bakewell - 23 May 2023 Form 4 Insider Report for TREACE MEDICAL CONCEPTS, INC. (TMCI)

Role
Director
Signature
/s/ Lisa Taylor as Attorney-in-fact for John K. Bakewell
Issuer symbol
TMCI
Transactions as of
23 May 2023
Net transactions value
$0
Form type
4
Filing time
25 May 2023, 21:00:21 UTC
Previous filing
17 Aug 2022
Next filing
26 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TMCI Common Stock Award $0 +2,753 +120% $0.000000 5,048 23 May 2023 Direct F1, F2
holding TMCI Common Stock 250,000 23 May 2023 Deborah M. Bakewell, as Trustee of family trust #1
holding TMCI Common Stock 92,300 23 May 2023 John K. Bakewell, as Trustee of family trust #2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TMCI Stock Option (Right to Buy) Award $0 +6,305 $0.000000 6,305 23 May 2023 Common Stock 6,305 $26.34 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents restricted stock units (RSUs) for which the Reporting Person is entitled to receive one (1) share of Issuer's Common Stock for each RSU upon vesting. The RSUs will be 100% vested on the earlier of (a) May 23, 2024 or (b) the date of the 2024 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through the vesting date. The Reporting Person voluntarily elected to defer receipt of the shares of the issuer's Common Stock issuable upon settlement of the RSUs until the earlier of (a) a change in control, (b) the Reporting Person's separation of service to the Issuer, or (c) the fifth anniversary of the RSU's grant date.
F2 Includes 2,753 RSUs.
F3 The stock option will vest in 12 substantially equal monthly installments, commencing on June 23, 2023, such that the stock option will be fully vested and exercisable on the earlier of (a) May 23, 2024, or (b) the date of the 2024 annual meeting of stockholders, subject to Reporting Person's providing continued service to Issuer through each vesting date.